Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine

AIDS

Volumn 21, Issue 5, 2007, Pages 547-563

  Yamamoto, Janet K ^a   Pu, Ruiyu ^a   Sato, Eiji ^a   Hohdatsu, Tsutomu ^b  

^a University of Florida College of Veterinary Medicine   (United States)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Feline immunodeficiency virus; Pathogenesis; T cell immunity; Vaccine; Virus neutralizing antibodies

Indexed keywords

EQUINE INFECTIOUS ANEMIA VIRUS VACCINE; FELINE LEUKEMIA VIRUS VACCINE; GAMMA INTERFERON; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; RECOMBINANT HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIGEN P24 VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOPTIVE TRANSFER; CELLULAR IMMUNITY; EDITORIAL; FELINE IMMUNODEFICIENCY VIRUS; FELINE IMMUNODEFICIENCY VIRUS INFECTION; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION; VIRUS INFECTION; VIRUS TRANSMISSION;

AIDS VACCINES; ANIMALS; CATS; DISEASE MODELS, ANIMAL; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; HIV INFECTIONS; HIV-1; IMMUNODEFICIENCY VIRUS, FELINE; VIRAL VACCINES; VIRULENCE;

EID: 33847218231     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328013d88a     Document Type: Editorial

References (207)

1. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987; 235:790-793.
2. SiebelinkKHJ, Chu I-H, Rimmelzwaan GF, Weijer K, Herwijnen RV, Knell P, et al. Feline immunodeficiency virus (FIV) infection in the cat as a model for HIV infection in man: FIV-induced impairment of immune function. AIDS Res Hum Retroviruses 1990; 6:1373-1378.
3. Yamamoto JK, Sparger E, Ho EW, Andersen H, O'Connor TP, Mandell CP, et al. Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats. Am J Vet Res 1988; 49:1246-1258.
4. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
5. Clavel F, Guetard D, Bru-Vezinet F, Chamaret S, Rey MA, Santos-Ferreira MO, et al. Isolation of a new human retrovirus from West African patients with AIDS. Science 1986; 233:343-346.
6. Miyazawa T, Tomonaga K, Kawaguchi Y, Mikami T. The genome of feline immunodeficiency virus. Arch Virol 1994; 134:221-234.
7. Gemeniano MC, Sawai ET, Sparger EE. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology 2004; 325:167-174.
8. Uhl EW, Heaton-Jones T, Pu R, Yamamoto JK. FIV vaccine development and its importance to veterinary and human medicine: a review. Vet Immunol Immunopath 2002; 90:113-132.
9. Heeney JL, Dagieish, AG, Weiss. Origins of HIV and the evolution of resistance to AIDS. Science 2006; 313:462-466.
10. Los Alamos National Laboratory. HIV and SIV nomenclature. http://www.hiv.lanl.gov/content/hiv-db/HelpDocs/subtypesmore.html [Accessed 25 October 2006].
11. Clapham PR, McKnight A. HIV-1 receptors and cell tropism. Br Med Bull 2001; 58:43-59.
12. Bhattacharya J, Peters PJ, Clapham PR. CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS 2003; 17:S35-S45.
13. Gottlieb GS, Hawes SE, Agne HD, Stern JE, Critchlow CW, Kiviat NB, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895-900.
14. Freel SA, Fiscus SA, Pilcher CD, Menezes P, Giner J, Patrick E, et al. Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variant in saliva and blood during primary infection. AIDS 2003; 17:2025-2033.
15. Bagnarelli P, Menzo S, Valenza A, Manzin A, Giacca M, Ancarani F, et al. Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS. J Virol 1992; 66:7328-7335.
16. Tachet A, Dulioust E, Salmon D, De Almeida M, Rivalland S, Finkielsztein L, et al. Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 1999; 13:823-831.
17. Shepard RN, Schock J, Robertson K, Shugars DC, Dyer J, Vernazza P, et al. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartment. J Clin Microbiol 2000; 38:1414-1418.
18. Hart CE, Lennox JL, Pratt-Palmore M, Wright TC, Schinazi RF, Evans-Strckfaden T, et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis 1999; 179:871-882.
19. Critchlow CW, Kiviat NB. Detection of human immunodeficiency virus type 1 and type 2 in the female genital tract: implications for the understanding of virus transmission. Obstet Gynecol Surv 1997; 52:315-324.
20. Shugars DC, Wahl SM. The role of the oral environment in HIV-1 transmission. J Am Dental Assoc 1998; 129:851-858.
21. Rousseau CM, Nduati RW, Richardson BA, Steele MS, John-Stewart GC, Mbori-Ngacha DA, et al. Longitudinal analysis of human immunodeficiency virus type 1 RNA in breast milk and of its relationship to infant infection and maternal disease. J Infect Dis 2003; 187:741-747.
22. O'Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, Sarge-Njie R, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. AIDS 2000; 14:441-448.
23. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu S-Y, Stewart PW, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785-1792.
24. Backe E, Jimenez E, Unger M, Schafer A, Vogel M. Fetal organs infected by HIV-1. AIDS 1993; 6:896-897.
25. Kuhn L, Stein ZA, Thomas PA, Singh T, Tsai W-Y. Maternal-infant HIV transmission and circumstances of delivery. Am J Public Health 1994; 84:1110-1115.
26. Oxtoby MJ. Perinatally acquired HIV infection. In: Pediatric AIDS. Edited by Pizzo P, Wilfert C. Baltimore: Williams & Wilkins; 1994. pp. 3-21.
27. Reeves JD, Doms RW. Human immunodeficiency virus type 2. J Gen Virol 2002; 83:1253-1265.
28. Popper SJ, Sarr AD, Gueye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J Virol 2000; 74:1554-1557.
29. Soriano V, Gomes P, Heneine W, Holguin A, Doruana M, Antunes R, et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000; 61:111-116.
30. Damon F, Descaps D, Fárfara I, Telles JN, Puyeo S, Campa P, et al. Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR. J Clin Microbiol 2001; 39:4264-4268.
31. Damon F, Gueudin M, Puyeo S, Fárfara I, Robertson DL, Descaps D, et al. Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections. J Clin Microbiol 2002; 40:3654-3659.
32. Sodora DL, Shpaer EG, Kitchell BE, Dow SW, Hoover EA, Mullins JI. Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. J Virol 1994; 68:2230-2238.
33. Bachmann MH, Mathiason-Dubard C, Learn GH, Rodrigo AG, Sodora DL, Mazzetti P, et al. Genetic diversity of feline immunodeficiency virus: Dual infection, recombination, and distinct evolutionary rates among envelope sequence clades. J Virol 1997; 71:4241-4253.
34. Nakamura K, Suzuki Y, Ikeo K, Sato E, Nguyen NTP, Gojobori T, et al. Phylogenetic analysis of Vietnamese isolates of feline immunodeficiency virus: genetic diversity of subtype C. Arch Virol 2003; 148:783-791.
35. Yamamoto JK, Torres BA, Pu R. Development of the dual-subtype FIV vaccine. AIDScience Vol. 2, No. 8 (online), April 2002, http://aidscience.org/Articles/AIDScience020.asp [Accessed 25 October 2006].
36. Kennedy JM, Hoke A, Zhu Y, Johnston JB, van Marke G, Silva C, et al. Peripheral neuropathy in lentivirus infection: evidence of inflammation and axonal injury. AIDS 2004; 18:1241-1250.
37. Shimojima M, Miyazawa T, Ikeda Y, McMonagle EL, Haining H, Akashi H, et al. Use ofCD134 as a primary receptor by the feline immunodeficiency virus. Science 2004; 303:1192-1195.
38. de Parseval A, Ngo S, Sun P, Elder JH. Factors that increase the effective concentration of CXCR4 dictate feline immunodeficiency virus tropism and kinetics of replication. J Virol 2004; 78:9132-9143.
39. Nakagaki K, Nakagaki K, Takahashi K, Schols D, De Clercq E, Tabira T. CXCR4 is the primary receptor for feline immunodeficiency virus in astrocytes. J Neurovirol 2001; 7:487-492.
40. Johnston JB, Power C. Feline immunodeficiency virus xenoinfection: the role of chemokine receptors and envelope diversity. J Virol 2002; 76:3626-3636.
41. Yamamoto JK, Hansen H, Ho EW, Morishita TY, Okuda T, Sawa TR, et al. Epidemiologic and clinical aspects of feline immunodeficiency virus (FIV) infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc 1989; 194:213-220.
42. Matteucci D, Baldinotti F, Mazzetti P, Pistello M, Bandecchi P, Ghilarducci R, et al. Detection of feline immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction. J Clin Microbiol 1993; 31:494-501.
43. Goto Y, Nishimura Y, Baba K, Mizuno T, Endo Y, Masuda K, et al. Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus. J Virol 2002; 76:10079-10083.
44. Ryan G, Klein D, Knapp E, Hosie MJ, Grimes T, Mabruk MJ, et al. Dynamics of viral and proviral loads of feline immunodeficiency virus within the feline central nervous system during the acute phase following intravenous infection. J Virol 2003; 77:7477-7485.
45. Vahlenkamp TW, Egberink HF, van Eijk MJT, Slotboom-Kamphorst AME, Verschoor EJ, Horzinek MC, et al. Competitive reverse transcription-polymerase chain reaction for quantitation of feline immunodeficiency virus. J Virol Methods 1995; 52:335-346.
46. Lui R, Hudson LC, Tompkins MB, Vahlenkamp TW, Colby B, Rundle C, et al. Cerebrospinal fluid is an efficient rout for establishing brain infection with feline immunodeficiency virus and transferring infectious virus to periphery. J Neuro Virol 2006; 12:294-306.
47. Hohdatsu T, Nakanishi T, Saito I, Koyama H. Ability of CD8+ T cell anti-feline immunodeficiency virus (FIV) activity and FIV proviral DNA load in mononuclear cells in FIV-infected cats. J Vet Med Sci 2005; 67:129-131.
48. Jordan HL, Howard J, Tompkins WA, Kennedy-Stoskopf S. Detection of feline immunodeficiency virus in semen from seropositive domestic cats (Felis catus). J Virol 1995; 69:7328-7333.
49. Jordan HL, Howard J, Sellon RK, Wildt DE, Tompkins WA, Kennedy-Stoskopf S. Transmission of feline immunodeficiency virus in domestic cats via artificial insemination. J Virol 1996; 70:8224-8228.
50. Jordan HL, Howard JG, Bucci JG, Butterworth JL, English R, Kennedy-Stoskopf S, et al. Horizontal transmission of feline immunodeficiency virus with semen from seropositive cats. J Reprod Immuno 1998; 41:341-357.
51. Burkhard MJ, Mathiason CK, O'Halloran K, Hoover EA. Kinetics of early FIV infection in cats exposed via the vaginal versus intravenous route. AIDS Res Hum Retrovir 2002; 18:217-226.
52. Allison RW, Hoover EA. Feline immunodeficiency virus is concentrated in milk early in lactation. AIDS Res Hum Retrovir 2003; 19:245-253.
53. Sellon RK, Jordan HL, Kennedy-Stoskopf S, Tompkins MB, Tompkins WA. Feline immunodeficiency virus can be experimentally transmitted via milk during acute maternal infection. J Virol 1994; 68:3380-3385.
54. O'Neil LL, Burkhard MJ, Hoover EA. Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats. J Virol 1996; 70:2894-2901.
55. Burkhard MJ, Obert LA, O'Neil LL, Diehl LJ, Hoover EA. Mucosal transmission of cell-associated and cell-free feline immunodeficiency virus. AIDS Res Hum Retrovir 1997; 13:347-355.
56. Kusuhara H, Hohdatsu T, Okumura M, Kayoko S, Suzuki Y, Motokawa K, et al. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet Microbiol 2005; 108:155-165.
57. Matteucci D, Poli A, Mazzetti P, Sozzi S, Bonci F, Isola P, et al. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol 2000; 74:10911-10919.
58. Burkhard MJ, Dean GA. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res 2003; 1:15-29.
59. D'Cruz OJ, Waurzyniak B, Uckun FM. Antiretroviral spermicide WHI-07 prevents vaginal and rectal transmission of feline immunodeficiency virus in domestic cats. Antimicrob Agents Chemother 2004; 48:1082-1088.
60. Stokes CR, Finerty S, Gruffydd-Jones TJ, Sturgess CP, Harbour DA. Mucosal infection and vaccination against feline immunodeficiency virus. J Biotechnol 1999; 73:213-221.
61. English RV, Johnson CM, Gebhard DH, Tompkins MB. In vivo lymphocyte tropism of feline immunodeficiency virus. J Virol 1993; 67:5175-5186.
62. Dow SW, Poss ML, Hoover EA. Feline immunodeficiency virus: a neurotropic lentivirus. J Acquir Immune Defic Syndr 1990; 3:658-668.
63. Hein A, Martin JP, Koehren F, Bingen A, Dorries R. In vivo infection of ramified microglia from adult cat central nervous system by feline immunodeficiency virus. Virology 2000; 268:420-429.
64. + T regulatory cells. J Immunol 2004; 172:4752-4761.
65. + T-regulatory cells correlates both with surface expression of CXCR4 and activation of FIV long terminal repeat binding cellular transcriptional factors. J Virol 2005; 79:4965-4976.
66. + regulatory T cells in HIV infection. Microbes Infect 2005; 7:1063-1065.
67. Miyazawa T. Evolution of lentiviruses and receptor specificity. Uirusu 2005; 55:27-34.
68. Salek-Ardakani S, Croft M. Regulation of CD4 T cell memory by OX40 (CD134). Vaccine 2006; 24:872-883.
69. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23:23-68.
70. Ackley CD, Yamamoto JK, Levy NB, Pedersen NC, Cooper MD. Immunologic abnormalities in pathogen-free cats experimentally infected with feline immunodeficiency virus. J Virol 1990; 64:5652-5655.
71. + cell numbers in cats with naturally acquired feline immunodeficiency virus infection. J Virol 1992; 66:1484-1488.
72. Torten M, Franchini M, Barlough JE, George JW, Mozes E, Lutz J, et al. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J Virol 1991; 65:2225-2230.
73. Taniguchi A, Ishida T, Washizu T, Tomoda I. Humoral immune response to T-cell dependent and independent antigens in cats infected with feline immunodeficiency virus. J Vet Med Sci 1991; 53:333-339.
74. Song W, Collison E, Billingsley P, Brown W. Induction of feline immunodeficiency virus specific cytotoxic T-cell responses from experimentally infected cats. J Virol 1992; 66:5409-5417.
75. Li J, Brown WC, Song W, Carpino MR, Wolf AM, Grant CK, et al. Retroviral vector-transduced cells expressing the core polyprotein induce feline immunodeficiency virus-specific cytotoxic T-lymphocytes from infected cats. Virus Res 1995; 38:93-109.
76. Choi IS, Hokanson R, Collisson EW. Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8(+) T lymphocytes suppresses FIV replication. J Virol 2000; 74:676-683.
77. Barlough JE, Ackley CD, George JW, Levy N, Acevedo R, Moore PF, et al. Acquired immune dysfunction in cats with experimentally induced feline immunodeficiency virus infection: comparison of short-term and long-term infection. J Acquir Immune Defic Syndr 1991; 4:219-227.
78. Gebhard DH, Dow JL, Childers TA, Alvelo JI, Tompkins MB, Tompkins WAF. Progressive expansion of an L-selectin-negative CD8 cell with anti-feline immunodeficiency virus (FIV) suppressor function in the circulation of FIV-infected cats. J Infect Dis 1999; 180:1503-1513.
79. Rideout BA, Moore PF, Pedersen NC. Persistent upregulation of MHC class II antigen expression on T-lymphocytes from cats experimentally infected with feline immunodeficiency virus. Vet Immunol Immunopathol 1992; 35:71-81.
80. Lehmann R, Franchini M, Aubert A, Wolfensberger C, Cronier J, Lutz H. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine. J Am Vet Med Assoc 1991; 199:1446-1452.
81. Dawson S, Smyth NR, Bennett M, Gaskell RM, McCracken CM, Brown A, et al. Effect of primary-stage feline immunodeficiency virus infection on subsequent feline calicivirus vaccination and challenge in cats. AIDS 1991; 5:747-750.
82. Inoshima Y, Ikeda Y, Kohmoto M, Pecoraro MR, Shimojima M, Shimojima Y, et al. Persistence of high virus neutralizing antibody titers in cats experimentally infected with feline immunodeficiency virus. J Vet Med Sci 1996; 58:925-927.
83. Hopper CD, Sparkes AH, Gruffydd-Jones TJ, Crispin SM, Muir P, Harbour DA, et al. Clinical and laboratory findings in cats infected with feline immunodeficiency virus. Vet Rec 1989; 125:341-346.
84. Boche D, Hurtrel M, Gray F, Claessens-Maire MA, Ganiere JP, Montagnier L, et al. Virus load and neuropathology in the FIV model. J Neurovirol 1996; 2:377-387.
85. Callanan JJ, Jones BA, Irvine J, Willett BJ, McCandlish IAP, Jarrett O. Histologic classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections. Vet Pathol 1996; 33:264-272.
86. Terry A, Callanan JJ, Fulton R, Jarrett O, Neil JC. Molecular analysis of tumors from feline immunodeficiency virus (FIV)-infected cats: an indirect role for FIV? Int J Cancer 1995; 61:227-232.
87. Hofmann-Lehmann R, Holznagel E, Ossent P, Lutz H. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets. Clin Diagn Lab Immunol 1997; 4:33-42.
88. Barker E, Mackewicz CE, Reyes-Teran G, Sato A, Stranford SA, Fujimura SH, et al. Virological and immunological features of long-term human immunodeficiency virus-infected individuals who have remained asymptomatic compared with those who have progressed to acquired immunodeficiency syndrome. Blood 1998; 92:3105-3114.
89. Levy JA. HIV pathogenesis and long-term survival. AIDS 1993; 7:1401-1410.
90. Bendinelli M, Pistello M, Lombardi S, Poli A, Garzelli C, Matteucci D, et al. Feline immunodeficency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev 1995; 8:87-112.
91. Fauci A, Schnittman S, Poli G, Koenig S, Pantaleo G. Immunopathogenic mechanisms of human immunodeficiency virus (HIV) infection. Ann Inter Med 1991; 114:678-693.
92. Henriksen SJ, Prospero-Garcia O, Phillips TR, Fox HS, Bloom FE, Elder JH. Feline immunodeficiency virus as a model for study of lentivirus infection of the central nervous system. Curr Top Microbiol Immunol 1995; 202:167-186.
93. Kaul M, Zheng J, Okamoto S, Gendelman HE, Lipton SA. HIV-1 infection and AIDS: consequences for the central nervous system. Cell Death Differentiation 2005; 12:878-892.
94. Morner A, Thomas JA, Bjorling E, Munson PJ, Lucas SB, McKnight A. Productive HIV-2 infection in the brain is restricted to macrophages/ microglia. AIDS 2003; 17:1451-1455.
95. Trillo-Pazos G, Diamanturos A, Rislove L, Menza T, Chao W, Belem P, et al. Detection of HIV-1 DNA in microglia/macrophages, astrocytes, and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol 2003; 13:144-154.
96. McAllister RH, Herns MV, Harrison MJG, Newman SP, Connolly S, Fowler CJ, et al. Neurological and neuropsychological performance in HIV seropositive men without symptoms. J Neurol Neurosurg Psychiatry 1992; 55:143-148.
97. Podell M, Oglebee M, Mthes L, Krakowka S, Olmsted R, Lafrado L. AIDS-associated encephalopathy with experimental feline immunodeficiency virus infection. J Acquir Immune Defic Syndr 1993; 6:758-771.
98. Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006; 3:28-39.
99. Petrucci A, Dorrucci M, Alliegro MB, Pezzotti P, Rezza G, Sinicco A, et al. Seroconversion Study Group. How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian seroconversion study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:2432-2248.
100. Lui K-J, Darrow WW, Rutherford GW. A model-based estimate of the mean incubation period for AIDS in homosexual men. Science 1988; 240:1333-1335.
101. Diehl LJ, Mathiason-Dubard CK, O'Niel LL, Obert LA, Hoover EA. Induction of accelerated feline immunodeficiency virus disease by acute-phase virus passage. J Virol 1995; 69:6149-6157.
102. Pu R, Coisman J, Coleman J, Sato E, Tanabe T, Arai M, et al. Dual-subtype FIV vaccine (Fel-O-Vax® FIV) protection against heterologous subtype B FIV isolate. Feline Med Surg 2005; 7:65-70.
103. Yamamoto JK. Current immunobiology of feline immunodeficiency virus: its importance to FIV vaccine [abstract]. 75th Annual Western Veterinary Conference, 2003, p. 75.
104. Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin Infect Dis 2002; 34:1108-1114.
105. Yamamoto JK, Sato E, Pu R, Coleman J, Martin M. Feline immunodeficiency virus vaccines: evolving concepts on a vaccine approaches. Cellscience Reviews Vol. 2, No. 3, Jan. 2006, http://www.cellscience.com/ journal/journalindex.asp [Accessed 25 October 2006].
106. Little SE. Feline immunodeficiency virus testing in stray, feral, and client-owned cats of Ottawa. Can Vet J 2005; 46:898-901.
107. Levy JK, Scott HM, Lachtara JL, Crawford PC. Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity. J Am Vet Med Assoc 2006; 228:371-376.
108. Mendes-de-Almeida F, Faria MC, Branco AS, Serrao ML, Souza AM, Almosny N, et al. Sanitary conditions of a colony of urban feral cats (Felis catus Linnaeus, 1758) in a zoological garden of Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo 2004; 46:269-274.
109. Grindem CB, Corbett WT, Ammerman BE, Tomkins MT. Seroepidemiologic survey of feline immunodeficiency virus infection in cats of Wake County, North Carolina. J Am Vet Med Assoc 1989; 194:226-228.
110. Dorny P, Speybroeck N, Verstraete S, Baeke M, De Becker A, Berkvens D, et al. Serological survey of Toxoplasma gondii, feline immunodeficiency virus and feline leukaemia virus in urban stray cats in Belgium. Vet Rec 2002; 151:626-629.
111. Sukura A, Grohn YT, Junttila J, Palolahti T. Association between feline immunodeficiency virus antibodies and host characteristics in Finnish cats. Acta Vet Scand 1992; 33:325-334.
112. Courchamp F, Yoccoz NG, Artois M, Pontier D. At-risk individuals in Feline Immunodeficiency Virus epidemiology: evidence from a multivariate approach in a natural population of domestic cats (Felis catus). Epidemiol Infect 1998; 121:227-236.
113. Fuchs A, Binzel L, Lonsdorfer M. Epidemiology of FeLV and FIV infection in the Federal Republic of Germany. Tierarztl Prax 1994; 22:273-277.
114. Hartmann K, Hinze K. Epidemiology and clinical aspects of FIV infection in Bavaria. Tierarztl Prax 1991; 19:545-551.
115. Peri EV, Ponti W, Dall'ara P, Rocchi M, Zecconi A, Bonizzi L. Seroepidemiological and clinical survey of feline immunodeficiency virus infection in northern Italy. Vet Immunol Immunopathol 1994; 40:285-297.
116. Bandecchi P, Matteucci D, Baldinotti F, Guidi G, Abramo F, Tozzini F, et al. Prevalence of feline immunodeficiency virus and other retroviral infections in sick cats in Italy. Vet Immunol Immunopathol 1992; 31:337-345.
117. Egberink HF, Hendriks P, Slappendel RJ, Horzinek MC. The diagnosis and epidemiology of feline immunodeficiency virus (FIV) infection in The Netherlands. Tijdschr Diergeneeskd 1993; 118:43S-44S.
118. Tryland M, Sandvik T, Holtet L, Nilsen H, Olsvik O, Traavik T. Antibodies to orthopoxvirus in domestic cats in Norway. Vet Rec 1998; 143:105-109.
119. Ueland K, Lutz H. Prevalence of feline leukemia virus and antibodies to feline immunodeficiency virus in cats in Norway. Zentralbl Veterinarmed B 1992; 39:53-58.
120. Duarte A, Taveres. Phylogenetic analysis of Portuguese feline immunodeficiency virus sequences reveals high genetic diversity. Vet Microbiol 2006; 114:25-33.
121. Arjona A, Escolar E, Soto I, Barquero N, Martin D, Gomez-Lucia E. Seroepidemiological survey of infection by feline leukemia virus and immunodeficiency virus in Madrid and correlation with some clinical aspects. J Clin Microbiol 2000; 38:3448-3449.
122. Lutz H, Lehmann R, Winkler G, Kottwitz B, Dittmer A, Wolfensberger C, et al. Feline immunodeficiency virus in Switzerland: clinical aspects and epidemiology in comparison with feline leukemia virus and coronaviruses. Schweiz Arch Tierheilkd 1990; 132:217-225.
123. Hosie MJ, Robertson C, Jarrett O. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom. Vet Rec 1989; 125:293-297.
124. Maruyama S, Kabeya H, Nakao R, Tananka S, Sakai T, Xuan X, et al. Seroprevalence of Bartonella henselae, Toxoplasma gondii, FIV and FeLV infections in domestic cats in Japan. Microbiol Immunol 2003; 47:147-153.
125. Uema M, Ikeda Y, Miyazawa T, Lin JA, Chen MC, Kuo TF, et al. Feline immunodeficiency virus subtype C is prevalent in northern part of Taiwan. J Vet Med Sci 1999; 61:197-199.
126. Nakamura K, Miyazawa T, Ikeda Y, Sato E, Nishimura Y, Nguyen NT, et al. Contrastive prevalence of feline retrovirus infections between northern and southern Vietnam. Vet Med Sci 2000; 62:921-923.
127. Malik R, Kendall K, Cridland J, Coulston S, Stuart AJ, Snow D, et al. Prevalences of feline leukaemia virus and feline immunodeficiency virus infections in cats in Sydney. Aust Vet J 1997; 75:323-327.
128. Friend SC, Birch CJ, Lording PM, Marshall JA, Studdert MJ. Feline immunodeficiency virus: prevalence, disease associations and isolation. Aust Vet J 1990; 67:237-243.
129. Hayward J, Taylor J, Rodrigo A. Kiwi cat FIV. Eighth International Feline Retrovirus Research Symposium, 2006, [abstract P10] p. 64.
130. Yilmaz H, Ilgaz A, Harbour DA. Prevalence of FIV and FeLV infections in cats in Istanbul. J Feline Med Surg 2000; 2:69-70.
131. Kakinuma S, Motokawa K, Hohdatsu T, Yamamoto JK, Koyama H. Nucleotide sequence of feline immunodeficiency virus: classification of Japanese isolates into two subtypes which are distinct from non-Japanese subtypes. J Virol 1995; 69:3639-3646.
132. PecoraroMR, Tomonaga K,MiyazawaT,Kawaguchi Y,Sugita S, Tohya Y, et al. Genetic diversity of Argentine isolates of feline immunodeficiency virus. J Gen Virol 1996; 77:2031-2035.
133. Tanabe T, Yamamoto JK. Phenotypic and functional characterization of FIV infection in bone marrow stroma. Virology 2001; 282:113-122.
134. Ikeda Y, Miyazawa T, Nishimura Y, Nakamura K, Tohya Y, Mikami T. High genetic stability of TM1 and TM2 strains of subtype B feline immunodeficiency virus in long-term infection. J Vet Med Sci 2004; 66:287-289.
135. Diehl LJ, Mathiason-Dubard CK, O'Neil LL, Hoover EA. Plasma viral RNA load predicts disease progression in accelerated feline immunodeficiency virus infection. J Virol 1996; 70:2503-2507.
136. Warren JT, Levinson MA. Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates. J Med Primatol 1995; 24:150-168.
137. Murthy KK, Cobb EK, Rouse SR, McClure HM, Payne JS, Salas MT, et al. Active and passive immunization against HIV type 1 infection in chimpanzees. AIDS Res Hum Retroviruses 1998; 3:S271-S276.
138. Warren J. Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates. J Med Primatol 2002; 31:237-256.
139. Leroux C, Cadore JL, Montelaro RC. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us? Vet Res 2004; 35:485-512.
140. Nayaran O, Joag SV, Stephens EB. Selected models of HIV-induced neurological disease. Curr Top Microbio Immunol 1995; 202:151-166.
141. Maanen M, Sutton RE. Rodent models for HIV-1 infection and disease. Cur HIV Res 2003; 1:121-130.
142. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258:1938-1941.
143. Desrosiers RC, Bolognesi DP. Controversies in science: a live virus AIDS vaccine? J NIH Res 1994; 6:54-62.
144. Baba TW, Jeong YS, Penninck D, Bronson R, Green MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995; 267:1820-1825.
145. Carl S, Iafrate AJ, Skowronski J, Stahl-Hennig C, Kirchhoff F. Effect of the attenuating deletion and of sequence alterations evolving in vivo on simian immunodeficiency virus C8-Nef function. J Virol 1999; 73:2790-2797.
146. Wyand MS, Manson KH, Garcia-Moll M, Montefiori C, Desrosiers RC. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 1996; 70:3724-3733.
147. Hosie MJ, Flynn JN, Rigby MA, Cannon C, Dunsford T, Machay NA, et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J Virol 1998; 72:7310-7319.
148. Lockridge KM, Chien M, Dean GA, Stefano Cole K, Montelaro RC, et al. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology 2000; 273:67-79.
149. Elder JH, Dean GA, Hoover EA, Hoxie JA, Malim MH, Mathes L, et al. Workshop Summary: lessons from the cat: feline immunodeficiency virus as a tool to develop intervention strategies against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1998; 14:797-801.
150. Okada S, Pu R, Young E, Stoffs W, Yamamoto JK. Super-infection of cats with FIV subtypes A and B. AIDS Res Hum Retroviruses 1994; 10:1739-1746.
151. Kyaw-Tanner MT, Robinson WF. Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection. Arch Virol 1996; 141:1703-1713.
152. Kyaw-Tanner MT, Greene WK, Park HS, Robinson WF. The induction of in vivo superinfection and recombination using feline immunodeficiency virus as the model. Arch Virol 1994; 138:261-271.
153. Ruprecht RM. Live attenuated AIDS viruses as vaccines: promise or peril? Immunol Rev 1999; 170:135-149.
154. Gardner MB. HIV vaccine development. In: The AIDS knowledge base, 2nd edn.. Edited by Kohen PT, Sande MA, Volberdine P.Boston: Little Brown, Co.; 1994. pp. 3.6-1-3.6-5.
155. Siegel F, Kurth R, Norley S. Neither whole inactivated virus immunogen nor passive immunoglobulin transfer protects against SIVagm infection in the African green monkey natural host. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:217-226.
156. Putkonen P, Bjorling E, Akerblom L, Thorstensson R, Lovgren K, Benthin L, et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J Acquir Immune Defic Syndr 1994; 7:551-559.
157. Rwambo PM, Issel CJ, Adams WV Jr, Hussain KA, Miller M, Montelaro RC. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection. Arch Virol 1990; 111:199-212.
158. Karlas JA, Siebelink KH, Peer MA, Huisman W, Cuisinier AM, Rimmelzwaan GF, et al. Vaccination with experimental feline immunodeficiency virus vaccines, fixed autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol 1999; 80:761-765.
159. Richardson J, Moraillon A, Baud S, Cuisinier AM, Sonigo P, Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 1997; 71:9640-9649.
160. Siebelink KHJ, Tijhaar E, Huisman RC. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 1995; 69: 3704-3711.
161. Elyar J, Tellier MC, Soos JM, Yamamoto JK. Perspectives on FIV vaccine development. Vaccine 1997; 15:1437-1444.
162. Pu R, Coleman J, Omori M, Mison M, Huang C, Arai M, et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 2001; 15:1-13.
163. Hesselink W, Sondermeijer P, Pouwels H, Verblakt E, Dhore C. Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge. Vet Microbiol 1999; 69:109-110.
164. Hoover EA, Mullins JI, Chu H-J, Wasmoen TL. Efficacy of an inactivated leukemia virus vaccine. AIDS Res Hum Retroviruses 1996; 12:379-383.
165. Omori M, Pu R, Tanabe T, Hou W, Coleman J, Arai M, et al. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. Vaccine 2004; 23:386-398.
166. Desrosiers RC. Prospects for an AIDS vaccine. Nat Med 2004; 10:221-223.
167. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC. Protection by live attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999; 73:8356-8363.
168. Fuller DH, Rajakumar PA, Wilson LA, Triche AM, Fuller JT, Shipley T, et al. Induction of mucosal protection against primary heterologous simian immunodeficiency virus by a DNA vaccine. J Virol 2002; 76:3309-3317.
169. Shiver JW, Fu T-M, Chen L, Casimiro DR, Davies M-E, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficency-virus immunity. Nature 2002; 415:331-335.
170. Amara RR, Smith JM, Staprans SI, Montefiori C, Villinger F, Altman JD, et al. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol 2002; 76: 6138-6146.
171. American Pet Products Manufacturers Association, Inc. APPMA's 2005/2006 national petowners survey. Industry Statistics & Trends (online), http//www.appma.org/press_industrytrends.asp [Accessed 25 October 2006].
172. AMFAR. About HIV/AIDS statistics: United States. http://www.amfar.org/ cgi-bin/iowa/abouthiv/index.html [Accessed 25 October 2006].
173. 2006 Compare infobase limited. Top ten pet cat population. http://www.mapsofworld.com/world-top-ten/maps/countries-by-pet-cat-population. jpg [Accessed 25 October 2006].
174. European Pet Food Industry Federation. Facts and figures: 60M cats in Europe. http://www.fediaf.org/gentree.htm [Accesed 25 October 2006].
175. th anniversary special edition). May 2006. http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp [Accessed 25 October 2006].
176. Pu R, Paredes G, Yamamoto JK. FIV vaccine update [proceeding]. Am Assoc Feline Practitioners 2004; 103-107.
177. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995; 69:5838-5842.
178. Omori M, Pu R, Yamamoto JK. Cellular and molecular analyses of protection induced by dual-subtype FIV vaccine. Sixth International Feline Retrovirus Research Symposium 2002, [abstract TP-3] p. 48.
179. Pu R, Okada S, Omori M, Rine SL, Lewis BA, Lipton E, et al. MHC-restricted protection of cats against FIV infection with adoptive transfer of immunocytes from FIV-vaccinated cats. Cellular Immunol 1999; 198:30-43.
180. Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK. HIV-1 p24 vaccine protects cats against FIV. AIDS 2005; 19:1457-1466.
181. Tizard IR (editor). Antibodies: soluble forms of BCR. In: Veterinary immunology: an introduction, 7th edn. Philadelphia: Elsevier; 2004. pp. 145-154.
182. Pastoret, PP (editor). Immunology of the cat. In: Handbook of vertebrate immunology. London: Academic Press Ltd; 1998. pp. 289-335.
183. Ruiyu P, Sato E, Yamamoto JK. Feline immunodeficiency virus (FIV)-cat model for AIDS: T-cell immunity important for prophylactic vaccine protection. XVI International Conference on AIDS, 2006 [abstract THP0016] p. 290.
184. Gorse GJ, Patel GB, Mandava MD, Belshe RB, National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complemetary in vitro stimulation strategies. Vaccine 2000; 18:835-849.
185. + T cells by primary HIV-1 infection. J Immunol 1997; 158:807-815.
186. + human CTL clones induced by candidate AIDS vaccine. J Immunol 1994; 153:2787-2799.
187. Holling TM, van der Stoep N, Quinten E, van den Elsen PJ. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III. J Immunol 2002; 168:763-770.
188. Gansbacher B, Zier KS. Regulation of HLA-DR, DP, and DQ expression in activated T cells. Cell Immunol 1988; 117:22-34.
189. Esser MT, Graham DR, Coren LV, Trubey CM, Bess JW Jr, Arthur LO, et al. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol 2001; 75:6173-6182.
190. Kestens L, Vanham G, Gigase P, Young G, Hannet I, Vanlangendonck F, et al. Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS 1992; 6:793-697.
191. Cantin R, Fortin JF, Lamontagne G, Tremblay M. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 1997; 71:1922-1930.
192. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15:617-648.
193. Truckenmiller ME, Norbury CC. Viral vectors for inducing CD8+ T cell responses. Expert Opin Biol Ther 2004; 4:861-868.
194. Los Alamos National Laboratory. Epitope maps. //hiv-web. lanl.gov/content/immunology/maps/maps.html [Accessed 25 October 2006].
195. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RP, Strick D, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003; 77:2081-2092.
196. Wade-Evans AM, Stott J, Hanke T, Stebbings R, Berry N, Lines J, et al. Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge. AIDS Res Hum Retroviruses 2001; 17:1517-1526.
197. Muthumani K, Bagarazzi M, Conway D, Hwang DS, Ayyavoo V, Zhang D, et al. Inclusion of Vpr accessory gene in a plasmid vaccine cocktail markedly reduces nef vaccine effectiveness in vivo resulting in CD4 cell loss and increased viral loads in rhesus macaques. J Med Primatol 2002; 31:179-185.
198. O'Brien SJ, Gao X, Carrington M. HLA and AIDS: a cautionary tale. Trends Mol Med 2001; 7:379-381.
199. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997; 3:212-217.
200. Belyakov IM, Berzofsky JA. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 2004; 20:247-253.
201. Kozlowski PA, Neutra MR. The role of mucosal immunity in prevention of HIV transmission. Curr Mol Med 2003; 3:217-228.
202. Enioutina EY, Visic D, Daynes RA. The induction of systemic and mucosal immune responses to antigen-adjvant composition administered into the skin: alterations in the migratory properties of dendritic cells appear to be important for stimulating mucosal immunity. Vaccine 2000; 18:2753-2767.
203. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:S45-S53.
204. Kozlowski PA, Williams SB, Lynch RM, Flanigan TP, Patterson RR, Cu-Uvin S, et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002; 169:566-574.
205. Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004; 113:998-1007.
206. Mestecky J, Jackson S, Moldoveanu Z, Nesbit LR, Kulhavy R, Prince SJ, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004; 20:972-988.
207. Haimovici F, Mayer KH, Anderson DJ. Quantitation of HIV-1-specific IgG, IgA, and IgM antibodies in human genital tract secretions. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:185-191.